User profiles for Lucía Trilla-Fuertes

Lucia Trilla-Fuertes

Hospital Universitario La Paz-IdiPAZ
Verified email at salud.madrid.org
Cited by 361

[HTML][HTML] Comprehensive characterization of the mutational landscape in localized anal squamous cell carcinoma

L Trilla-Fuertes, I Ghanem, J Maurel, G Laura… - Translational …, 2020 - Elsevier
Anal squamous cell carcinoma (ASCC) is a rare neoplasm. Chemoradiotherapy is the
standard of care, with no therapeutic advances achieved over the past three decades. Thus, a …

[HTML][HTML] A novel approach to triple-negative breast cancer molecular classification reveals a luminal immune-positive subgroup with good prognoses

G Prado-Vázquez, A Gámez-Pozo, L Trilla-Fuertes… - Scientific reports, 2019 - nature.com
Triple-negative breast cancer is a heterogeneous disease characterized by a lack of hormonal
receptors and HER2 overexpression. It is the only breast cancer subgroup that does not …

MiRNAs in renal cell carcinoma

J Miranda-Poma, L Trilla-Fuertes… - Clinical and …, 2022 - Springer
MicroRNAs (miRNAs) are small RNA sequences that act as post-transcriptional regulatory
genes to control many cellular processes through pairing bases with a complementary …

[HTML][HTML] Functional proteomics outlines the complexity of breast cancer molecular subtypes

A Gámez-Pozo, L Trilla-Fuertes, J Berges-Soria… - Scientific Reports, 2017 - nature.com
Breast cancer is a heterogeneous disease comprising a variety of entities with various
genetic backgrounds. Estrogen receptor-positive, human epidermal growth factor receptor 2-…

[HTML][HTML] Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics

A Gámez-Pozo, L Trilla-Fuertes, G Prado-Vázquez… - PLoS …, 2017 - journals.plos.org
Background Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers
and usually requires the administration of adjuvant chemotherapy after surgery but even …

[HTML][HTML] Synergistic effect of antimetabolic and chemotherapy drugs in triple-negative breast cancer

E López-Camacho, L Trilla-Fuertes… - Biomedicine & …, 2022 - Elsevier
The triple-negative breast cancer (TNBC) subtype comprises approximately 15% of all breast
cancers and is associated with poor long-term outcomes. Classical chemotherapy remains …

[HTML][HTML] Protein content of blood-derived extracellular vesicles: An approach to the pathophysiology of cerebral hemorrhage

…, MDP Chantada-Vázquez, L Trilla-Fuertes… - Frontiers in Cellular …, 2023 - frontiersin.org
Extracellular vesicles (EVs) participate in cell-to-cell paracrine signaling and can be biomarkers
of the pathophysiological processes underlying disease. In intracerebral hemorrhage, …

Functional proteomics of colon cancer Consensus Molecular Subtypes

…, A Custodio, JÁ Fresno Vara, L Trilla-Fuertes - British Journal of …, 2024 - nature.com
Background The Colorectal Cancer Subtyping Consortium established four Consensus
Molecular Subtypes (CMS) in colorectal cancer: CMS1 (microsatellite-instability [MSI], Immune), …

Isotopologue multipoint calibration for proteomics biomarker quantification in clinical practice

C Chiva, O Pastor, L Trilla-Fuertes… - Analytical …, 2019 - ACS Publications
Targeted proteomics has become the method of choice for biomarker validation in human
biopsies due to its high sensitivity, reproducibility, accuracy, and precision. However, for …

[HTML][HTML] Biological molecular layer classification of muscle-invasive bladder cancer opens new treatment opportunities

L Trilla-Fuertes, A Gámez-Pozo, G Prado-Vázquez… - BMC cancer, 2019 - Springer
Background Muscle-invasive bladder tumors are associated with a high risk of relapse and
metastasis even after neoadjuvant chemotherapy and radical cystectomy. Therefore, further …